# Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia

> **NCT03348033** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hospital de Clinicas de Porto Alegre** · enrollment: 5 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** Chronic Myeloid Leukemia + NK cell

## Key facts

- **NCT ID:** NCT03348033
- **Lead sponsor:** Hospital de Clinicas de Porto Alegre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03
- **Primary completion:** 2021-03
- **Final completion:** 2023-03
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2019-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03348033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03348033, "Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03348033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*